title: Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens.
abstract: B-cell-type chronic lymphocytic leukemia (B-CLL) patients have immunological abnormalities of both B and T lymphocytes. Since T cell defects might depend upon a defective accessory function of neoplastic B lymphocytes, we analyzed the ability of peripheral blood B cells of seven B-CLL patients to stimulate allogenic normal T cells in mixed lymphocyte reaction (MLR) and to present tetanus toxoid (TT) to autologous T cells. In both systems, neoplastic B lymphocytes show a defective antigen-presenting function, which is more evident with disease progression. Such a defect cannot be ascribed to a decreased MHC class II molecule expression nor to an abnormal IL-1 beta production, but it can be partially accounted for by a low B7 expression. Pretreatment of neoplastic B cells with interleukin-4 (IL-4) restores primary MLR, but has little effect on the response to TT. The effect of IL-4 is not mediated by quantitative modifications of class II and B7 molecule expression or of IL-1 beta production.
authors.affiliation: Istituto di Semeiotica Medica, Quarta Cattedra di Medicina Interna, Padova, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Dazzi
authors.forename: E
authors.initials: E
authors.lastname: D'Andrea
authors.forename: G
authors.initials: G
authors.lastname: Biasi
authors.forename: G
authors.initials: G
authors.lastname: De Silvestro
authors.forename: G
authors.initials: G
authors.lastname: Gaidano
authors.forename: M
authors.initials: M
authors.lastname: Schena
authors.forename: T
authors.initials: T
authors.lastname: Tison
authors.forename: F
authors.initials: F
authors.lastname: Vianello
authors.forename: A
authors.initials: A
authors.lastname: Girolami
authors.forename: F
authors.initials: F
authors.lastname: Caligaris-Cappio
mesh_terms: D017951:Antigen Presentation; D001402:B-Lymphocytes / Q000276:immunology*; D002478:Cells, Cultured; D006684:HLA-DR Antigens / Q000502:physiology; D000949:Histocompatibility Antigens Class II / Q000494:pharmacology; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000494:pharmacology; D007519:Isoantigens / Q000276:immunology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000378:metabolism; D008213:Lymphocyte Activation / Q000276:immunology; D007959:Lymphocyte Culture Test, Mixed; D012995:Solubility; D013601:T-Lymphocytes / Q000276:immunology; D013745:Tetanus Toxoid / Q000276:immunology / Q000494:pharmacology; D013997:Time Factors
chemical_list: D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D007375:Interleukin-1; D007519:Isoantigens; D013745:Tetanus Toxoid; D015847:Interleukin-4